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ABSTRACT 
Experimental and Computational Investigations of Therapeutic Drug Release from 
Biodegradable Poly(lactide-co-glycolide) (PLG) Microspheres. (December 2007) 
Nader Samir Berchane, B.E., American University of Beirut; 
M.S., Texas A&M University 
Co-Chairs of Advisory Committee: Dr. Malcolm J. Andrews 
                                                                                Dr. Allison C. Rice-Ficht  
 
The need to tailor release-rate profiles from polymeric microspheres remains one of 
the leading challenges in controlled drug delivery. Microsphere size, which has a 
significant effect on drug release rate, can potentially be varied to design a controlled 
drug delivery system with desired release profile. In addition, drug release rate from 
polymeric microspheres is dependent on material properties such as polymer molecular 
weight. Mathematical modeling provides insight into the fundamental processes that 
govern the release, and once validated with experimental results, it can be used to tailor a 
desired controlled drug delivery system.  
To these ends, PLG microspheres were fabricated using the oil-in-water emulsion 
technique. A quantitative study that describes the size distribution of poly(lactide-co-
glycolide) (PLG) microspheres is presented. A fluid mechanics-based correlation that 
predicts the mean microsphere diameter is formulated based on the theory of 
emulsification in turbulent flow. The effects of microspheres’ mean diameter, 
polydispersity, and polymer molecular weight on therapeutic drug release rate from 
  
iv 
poly(lactide-co-glycolide) (PLG) microspheres were investigated experimentally. Based 
on the experimental results, a suitable mathematical theory has been developed that 
incorporates the effect of microsphere size distribution and polymer degradation on drug 
release. In addition, a numerical optimization technique, based on the least squares 
method, was developed to achieve desired therapeutic drug release profiles by 
combining individual microsphere populations. 
The fluid mechanics-based mathematical correlation that predicts microsphere mean 
diameter provided a close fit to the experimental results. We show from in vitro release 
experiments that microsphere size has a significant effect on drug release rate. The initial 
release rate decreased with an increase in microsphere size. In addition, the release 
profile changed from first order to concave-upward (sigmoidal) as the microsphere size 
was increased. The mathematical model gave a good fit to the experimental release data. 
Using the numerical optimization technique, it was possible to achieve desired release 
profiles, in particular zero-order and pulsatile release, by combining individual 
microsphere populations at the appropriate proportions. 
Overall, this work shows that engineering polymeric microsphere populations having 
predetermined characteristics is an effective means to obtain desired therapeutic drug 
release patterns, relevant for controlled drug delivery. 
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1. INTRODUCTION 1 
Humans have always attempted to improve their health by administrating therapeutic 
drugs. Modern science has produced numerous active agents that manipulate the 
biological environment within us; however, the effectiveness of these agents has been 
limited due to the inability to deliver these agents at the right time and in the right 
amounts. In recent years, increasing attention has been given to methods by which active 
agents are administered giving rise to the field of controlled release drug delivery which 
offers temporal and/or spatial control over the release of therapeutic drugs.   
 
1.1. Controlled Drug Delivery 
Controlled drug delivery offers several advantages compared with conventional drug 
release formulations, in particular: reduced toxicity, improved patient compliance and 
convenience, and site directed drug delivery [1]. 
Controlled drug delivery promises an increase for the shelf life of a drug, and offers 
the flexibility of controlled release kinetics for the administered drug. An ideal drug 
delivery system is one which provides the therapeutic drug at the desired site of action 
and in the minimum concentration required to produce the desired therapeutic effects. 
However, as a drug is administered through conventional release formulations, the drug 
concentration first rises rapidly to a maximum, and then slowly falls as the drug gets 
metabolized, excreted or degraded (Figure 1.1). Two critical drug concentration levels 
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are the minimum effective concentration (MEC) and the maximum safe concentration 
(MSC), as depicted in Figure 1.1. With conventional release formulations, it is difficult 
to maintain the drug concentration between the minimum effective and toxic levels 
because this type of formulation tends to first overdose and then underdose the site of 
application. Controlled release systems can be designed to overcome this limitation by 
balancing the rate of drug delivery to the rate of drug removal from the site of 
application. It is evident from Figure 1.1 that a controlled release formulation maintains 
an effective drug concentration for prolonged periods, and thus fewer applications of the 
active agent are required. Reduced frequency of administration significantly improves 
patient compliance and convenience with a consequent improvement in the efficacy of 
the treatment. In addition to the temporal control over the therapeutic drug release, 
controlled release formulations enable the local delivery of the drug and its containment 
at the site of action. This produces high and effective drug concentrations locally but 
avoids systematic side effects as the therapeutic drug is metabolized locally and does not 
enter the system’s circulation. 
Drug delivery patterns from a controlled release system can vary over a wide range, 
but it is important to introduce two main categories of release profiles [1]. In the first 
category, the drug release remains constant with time until the drug is completely 
released. The release rate can then be mathematically expressed as: 
 
k
dt
dM
=                                                           (1.1) 
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Figure 1.1 Concentration profiles for conventional and controlled release formulations. 
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where M is  mass of drug released, t is time, and k is a constant. This pattern of release is 
called zero-order release. The second common type of release profile is the first-order 
release, where the release rate is proportional to the mass of drug contained within the 
device. The release rate can then be mathematically expressed as: 
 
)( 0 MMk
dt
dM
−=                                                          (1.2) 
 
where M0 is mass of drug contained within the device at t0. In this type of release profile, 
the release rate declines exponentially with time until the device is exhausted of the 
drug: 
 
 )exp(0 ktkM
dt
dM
−=                                                       (1.3) 
 
1.2. Classification of Controlled Drug Delivery Systems  
There are five major types of controlled release systems [1,2]: 
• Diffusional systems (reservoir and monolithic) 
• Chemically controlled systems (biodegradable systems) 
• Combination of diffusional and biodegradable systems 
• Osmotic systems 
• Mechanical pumps 
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In diffusion controlled drug release systems, a substance is released from a device by 
permeation from its interior to the surrounding. There are two main types of diffusion 
controlled systems, the reservoir system and the monolithic system. As depicted in 
Figure 1.2, in the diffusion controlled reservoir system the active agent is enclosed by an 
inert outer membrane. As a consequence, the drug release rate from this type of system is 
dependent on the thickness, and the material properties of the membrane. Thin spots or 
pinholes could lead to catastrophic failure in this type of system, and quality control 
requirements make fabrication of a reservoir system usually more expensive and difficult 
than of a monolithic system because the membrane properties must be controlled 
carefully [1,2]. In a monolithic system, the drug is homogenously dissolved or dispersed 
through-out the rate controlling polymer matrix, as depicted in Figure 1.2. If the active 
agent is dissolved in the polymer matrix, then the device is called monolithic solution, 
while if the drug is dispersed as a solid, the system is called monolithic dispersion [1]. 
The release pattern from diffusion controlled systems depends on the geometry of the 
system, and the identity and nature of the carrier material.  
In a chemically controlled system, the release of the active agent occurs by either 
gradual bioerosion of the drug containing polymer matrix, or by cleavage of unstable 
bonds by which the drug is coupled to the polymer matrix [2]. As a consequence, the 
drug release rate from a purely chemically controlled system is governed by the 
biodegradation process. Alternatively, a biodegradable polymer can be utilized to prepare  
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Figure 1.2 Two main types of diffusion controlled systems: reservoir and monolithic. 
 
  
7 
a diffusion based drug delivery device. If polymer degradation occurs while the active 
agent is being released, then the release is determined by both the diffusion and the 
biodegradation process. In contrast, devices can be designed to biodegrade long after the 
drug is exhausted which eliminates the need for their surgical removal. 
Mechanical pumps [3] were among the first reliable controlled release delivery 
systems. More recent pumps have been small enough to be made implantable [1]. In 
contrast, the development of osmotic pumps [3] is more recent. Osmotic systems utilize 
osmotic effects to control the release of the active agent. The osmotic pressure developed 
by diffusion of water across a semi permeable membrane into a salt solution pushes a 
solution of the active agent from the device. These devices have been used as 
implantable systems and in simple oral tablet formulations [1,4]. 
 
1.3. Biodegradable Polymers 
Biodegradable polymers have been used to prepare a number of devices for 
controlled release, such as implants (microchips [5], disks [6-8]), and micro and 
nanospheres [9]. The linear polyesters are the most widely investigated type of 
biodegradable polymers. The most important of these esters are poly(lactide) (PL), 
poly(glycolide) (PG) and their copolymer poly(lactide-co-glycolide) (PLG) (Figure 1.3). 
PLG based drug delivery devices are attractive because of their biocompatibility, 
biodegradability, and non-toxicity. In addition, drug release from these synthetic 
polymers is dependent on properties such as polymer molecular weight and 
lactide:glycolide ratio [10]. By selection of an appropriate polymer composition with a  
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Figure 1.3 Chemical structure of (a) poly(lactide), (b) poly(glycolide), and (c) poly(lactide-co-
glycolide). 
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known rate of degradation, such polymers can be exploited to produce a drug delivery 
system that releases active agents at predetermined rates.  
The hydrolysis of aliphatic polyesters starts with water uptake followed by random 
hydrolytic splitting of the ester bonds which yields a carboxyl end group and a hydroxyl 
one. The thus formed carboxyl end groups are capable of catalyzing hydrolysis of other 
ester bonds, in a phenomenon called autocatalysis [11-14]. This hydrolytic degradation 
process occurs in the bulk of the polymer and is thus macroscopically homogeneous 
(bulk degradation). As a consequence of the polymer degradation process, the average 
molar mass decreases significantly before any weight loss takes place [11-13, 15]. This 
weight loss occurs at a molecular weight of 5000 – 10000 Da, when oligomers are 
produced that can dissolve in the diffused solvent. [11-13].  
 
1.4. Microspheres as Drug Delivery Devices 
Most traditional biodegradable drug delivery systems involve either entrapping a 
drug into biodegradable polymer matrices and surgically implanting it into the body [5-
8], or entrapping the drug into polymeric nano and micro spheres [9]. Microspheres (and 
nanospheres) are very versatile drug delivery vehicles, and can be administered through 
a variety of routes such as inhalation [16,17], oral [18], and parenteral routes [16]. The 
parenteral route includes subcutaneous [19], intravenous [20], and intramuscular [21] 
injection. This variety in the administration routes coupled with the ability to tailor the 
size of the microspheres enables site directed drug delivery. Also the first pass effect 
inherent in the oral route can be eliminated. Microspheres can be easily prepared from 
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biodegradable polymers and do not require implantation or explantation. In addition, 
various factors, such as size, polymer composition and molecular weight, can be used to 
tailor the drug release profiles from these devices [10,22-24]. Due to these attractive 
properties, microspheres occupy a unique position in drug delivery technology, and have 
shown to control release profiles for drugs having a wide range of molecular weights 
(small molecules [25-29], steroids [30], and proteins [31-37]).  
 
1.4.1. Fabrication Techniques 
Biodegradable polymeric microspheres encapsulating a therapeutic agent are often 
prepared by coacervation, spray drying, or solvent evaporation/extraction techniques 
[1,38-40]: 
 Coacervation [41] was the first microencapsulation technique used to prepare 
microspheres, and usually involves 4 steps. Initially the active agent is dissolved or 
dispersed in an organic polymer solution. The polymer is then forced to slowly phase 
separate which yields two liquid phases, the polymer containing coacervate phase and 
the supernatant phase depleted in polymer. The coacervate phase then gets adsorbed 
around the drug particles to form very soft coacervate droplets which entrap the drug. In 
the final stage of this process the microdroplets are dehydrated and hardened to form the 
final microspheres [1,38,39,41]. 
As previously mentioned, the spray drying method is also used to prepare polymeric 
microspheres [31, 42]. In this technique, a solution of the polymer, the drug and the 
organic solvent is prepared and then atomized, and air is usually used as the drying agent 
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to dry the particles. A major problem encountered while using this technique is the 
formation of polymer fibers due to insufficient breaking force applied by the nozzle 
[31,39,42].      
The most common technique currently used to prepare polymeric microspheres for 
controlled drug delivery is the solvent evaporation/extraction technique [30,40,43-48]. 
This technique can be divided into the single emulsion process used to entrap water-
insoluble drugs, and the double emulsion process used to entrap water-soluble drugs. In 
the single emulsion process, the polymer and the drug to be encapsulated are dissolved 
or dispersed in an organic solvent to form an organic solution. This organic solution is 
then added to a large-volume aqueous solution which results in an oil-in-water (o-w) 
emulsion (Figure 1.4). The emulsion is then stirred at high speeds to form fine droplets. 
The aqueous solution usually contains a polymer to prevent droplet aggregation. The 
organic solvent is then removed either by slowly evaporating under reduced pressure 
(solvent evaporation) or by quick extraction through addition of large volumes of de-
ionized water (solvent extraction) [1,30,38,39,43,44]. In the double emulsion process, 
the water-soluble drug is dissolved in an aqueous solvent, while the polymer is dissolved 
in an organic solvent. The aqueous solution is then emulsified in the organic solution 
with vigorous stirring to form the first water-in-oil emulsion (w-o). This emulsion is then 
added to a large-volume of aqueous solution to form a water-in-oil-in-water (w-o-w) 
emulsion. This emulsion is then subjected to solvent removal by either evaporation or 
extraction as in the single emulsion process [1,38,39,45-48]. 
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Aqueous Solvent 
Organic Solvent / Polymer / Drug Solution  
Emulsified Droplets 
 
Figure 1.4 Basics of the single emulsion solvent extraction/evaporation microsphere preparation 
technique. 
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1.5. Desired Drug Release Patterns 
Controlled drug release formulations should be designed to achieve drug release 
patterns that produce the optimal therapeutic response. Some therapeutics requires a 
constant release for a wide range of durations (days to months) [49-51], while for other 
therapeutics, sustained or continuous release is not optimal [5, 51-54].  In addition to the 
traditional zero-order release kinetics, pulsatile release (or pulsed release) is also of 
interest to the pharmaceutical industry (Figure 1.5). For example, in antigen delivery, 
pulsatile release is often more effective than sustained release profile [51], and a vaccine 
preparation could be designed to deliver two timed-release pulses of antigen from a 
single injection which would eliminate the need for a “booster” vaccination. Through 
this immunization formulation, an initial burst release of antigen in the first several days 
will induce the primary immune response, and after a period of weeks, during which 
little antigen is released, the system will deliver a second pulse of antigen release. Thus, 
the release pattern will mimic the release obtained from two different administrations 
[51]. Other examples include the release of insulin and hormones of the anterior pituitary 
gland such as growth hormone and the gonadotropin-releasing hormone (GnRH). These 
molecules are secreted by the human body in a pulsatile manner [53,54], and a delivery 
system that mimics the natural pulsatile release profile is desirable. 
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Figure 1.5 Schematic of ideal desired release profiles for controlled drug delivery: (a) pulsatile 
release, and (b) constant release. 
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1.6. Commercially Available Controlled Drug Release Formulations 
A considerable number of controlled release formulations are becoming 
commercially available, and Table 1.1 includes a list of currently marketed poly(lactide) 
and poly(lactide-co-glycolide) microsphere formulations. [55-62]. As depicted in Table 
1.1, polymeric microsphere formulations are versatile and have been used to entrap a 
wide range of drugs (small molecules, peptides, and proteins), having a wide range of 
molecular weight (410 Da – 22,000 Da). These drugs are used to treat a variety of 
indications which include periodontal diseases, prostate cancer, endometriosis, growth 
deficiency, acromegaly, and schizophrenia. In addition, these formulations have 
successfully achieved sustained drug release for time periods that range from days to 
months [57-62].  
 
1.7. Motivation and Organization   
Difficulty achieving desired release rates remains to be one of the main challenges in 
controlled drug delivery. The aim of this work is to investigate different methodologies 
that can be utilized to design a delivery system with desired release kinetics. This is done 
by preparing polymeric microspheres of specified mean diameter and size distribution 
and examining the effect of microsphere size and polymer molecular weight on in vitro 
release. A mathematical model is then developed which can be a useful tool to predict 
drug release from polymeric microspheres. In addition to modulating release kinetics by 
controlling microsphere size and polymer molecular weight, a numerical optimization  
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Table 1.1 List of FDA approved drug delivery products using PL and PLG polymers 
Product Pharmaceutical/ Mw (Da) Indication for use Duration of 
action 
Atridox 
Lupron Depot 
Trelsar Depot 
Suprecur MP 
Nutropin 
Sandostatin LAR 
Somatuline 
Arestin 
Risperdal Consta 
Zoladex 
Doxycycline/444 
Leuprolide/1209 
Triptorelin/1311 
Buserelin/1299 
Human Growth Hormone/22000  
Octreotide/1019 
Lanreotide 
Minocycline/457  
Risperidone/(410)  
Goserelin acetate/(1269) 
Periodontal disease 
Prostate cancer, endometriosis 
Prostate cancer 
Endometriosis 
Growth deficiency 
Acromegaly 
Acromegaly 
Periodontitis 
Schizophrenia 
Prostate cancer, endometriosis  
1 week 
1,3,4 months 
1 month 
1 month 
2 weeks,1 month 
1 month 
1 month 
2 weeks 
2 weeks 
1,3 months 
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technique is developed to achieve desired drug release profiles by mixing appropriate 
proportions of individual microsphere preparations.  
Section 2 of this dissertation investigates the mean diameter and size distribution of 
PLG microspheres prepared using the oil-in-water emulsion technique. Section 3 covers 
computational and experimental work done to investigate the effect of mean diameter 
and polydispersity of PLG microspheres on drug release. Section 4 covers work done to 
design desired drug release profiles by combining microsphere populations having 
different microsphere size and polymer molecular weight. 
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2. MEAN DIAMETER AND SIZE DISTRIBUTION OF PLG 
MICROSPHERES*
 2
 
2.1. Background 
Controlled drug delivery offers numerous advantages compared with conventional 
free dosage forms, in particular: improved efficacy, reduced toxicity, and improved 
patient compliance and convenience. Consequently there is considerable interest from 
the pharmaceutical industry about the encapsulation of vaccines and drugs in 
biodegradable proteinaceous or polymeric micro- and nano-spheres. Microencapsulation 
promises an increase for the shelf life of a vaccine, and offers the flexibility of controlled 
release kinetics for the administered drug [9].  
Commonly used microspheres in drug delivery include: polylactide (PL), 
polyglycolide (PG), poly(lactide-co-glycolide) (PLG), albumin, and alginate [9, 63-65]. 
PLG based microspheres are attractive macromolecular (drugs/vaccines) carriers 
because of their biocompatibility, biodegradability and non-toxicity. In addition, these 
synthetic polymers degrade at a rate that is dependent on properties such as polymer 
molecular weight and lactide:glycolide ratio [10]. By selection of an appropriate 
polymer composition with a known rate of degradation, such polymers can be exploited 
to produce a drug delivery system that releases active agents at predetermined rates. In 
                                                 
*Part of the data reported in this section is reprinted with permission from N.S. Berchane, F.F. Jebrail, 
K.H. Carson, A.C. Rice-Ficht, and M.J. Andrews, About mean diameter and size distributions of 
poly(lactide-co-glycolide) (PLG) microspheres, Journal of Microencapsul. 23 (2006) 539-552, Taylor and 
Francis. 
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addition, PLG microspheres are versatile, and can be prepared using the oil-in-water 
(o/w) emulsion solvent evaporation technique which was shown to successfully entrap 
hydrophobic materials [30, 43, 44]. Alternatively, PLG microspheres can be prepared 
through the (water-in-oil)-in-water (w-o-w) solvent evaporation technique that has been 
shown to be efficient in entrapping water soluble material [45-48].    
Drug release kinetics primarily depends on microsphere size and composition. In 
addition, microsphere size plays a crucial role when targeting a particular site in the 
body. For example, bioadherent microspheres of size less than 10 µm are absorbed by 
the intestinal lining in Peyer’s patches, while larger microspheres pass through without 
being affected. Despite the importance of microsphere size, little work has been done to 
quantitatively predict the distribution of microspheres from manufacturing techniques. 
Jeffery et al. [44] investigated the effect of various process parameters on microsphere 
size. Jeffery found that an increase in the rate of agitation resulted in a reduction in 
droplet size. In addition, it was also found that the choice of stabilizer significantly 
affects droplet size. However, it appears that no effort was made to relate these 
parameters to the physics of droplet formation [44]. Giletto [66] performed a study to 
determine PLG microsphere size and surface morphology, and scanning electron 
micrographs qualitatively showed that polymer molecular weight played a significant 
role in controlling microsphere size [66]. Berkland et al. [67] developed a method to 
produce microspheres of a monodisperse size distribution by spraying a polymer-
containing solution through a nozzle. The nozzle was equipped with acoustic excitation 
and a non-solvent carrier stream to produce uniform droplets [67]. Bahukudumbi et al. 
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[68] employed the turbulent dispersion theory to develop a mathematical correlation for 
the average diameter of bovine serum albumin (BSA) microspheres. 
In this Section we describe work to prepare PLG microspheres using the oil-in-water 
(o/w) emulsion solvent extraction technique. Microsphere diameter has been related to 
the size of the stable droplets formed in the emulsion. Turbulent dispersion theory is 
used to consider the different working parameters, and construct a correlation that 
predicts the final mean droplet size of the PLG emulsion. 
 
2.2. Materials and Methods 
2.2.1. Materials 
The poly(D,L-lactide-co-glycolide) used had a copolymer composition of 50:50, and a 
Mw of 50 – 75 kDa. The Poly (vinyl-alcohol) (PVA) was 87%-89% hydrolyzed, with a 
Mw of 13-23 kDa, and the Dichloromethane used had a molecular weight of 84.93 Da. 
All these chemicals and other miscellaneous items were purchased from Sigma (St. 
Louis, MO, USA).  
 
2.2.2. Microsphere Preparation  
PLG microspheres were prepared by the oil-in-water (o/w) emulsion solvent 
extraction technique described next, and depicted in Figure 2.1. The protocol is detailed 
in the literature [30,43,44]. PLG was dissolved in dichloromethane (DCM) to yield a 
10% (w/v) PLG solution. PVA solution (8% w/v) was stirred at the desired stirring speed  
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Dichloromethane (DCM) 
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Figure 2.1 Schematic of PLG microsphere preparation procedure. 
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for 5 minutes in a 400 ml Pyrex beaker with a Caframo ultra high torque stirrer (model 
BDC1850) having a speed range of 0 -1800 rpm. The PLG solution was slowly added to 
the beaker and stirring was continued for 60 minutes. Afterwards, the resulting emulsion 
was added to 1L of double distilled water, and stirring was continued for an additional 90 
minutes at a speed of 1200 rpm. Microspheres were then collected by filtration, where 
the filter size used was 0.2 µm to prevent any loss of microspheres. 
 Like others [44], we were not able to produce PLG microspheres without a stabilizer. 
Typical stabilizers used at the DCM/water interface include: Poly (vinyl alcohol) (PVA), 
sodium dodecyl sulphate (SDS), cetyltrimethyl ammonium bromide (CTAB), and 
methylcellulose. PVA was used in this research because it gave the smallest 
microspheres [44]. 
 
2.2.3. Microsphere Characterization 
Imaging of microspheres was performed with a LEO-VP1530 field emission 
scanning electron microscope at the Microscopy and Imaging Center (MIC) at Texas 
A&M University. Samples of the spheres were mounted on aluminum stubs using double 
adhesive tape. The stubs were then left overnight in a desiccator to dry. The samples 
were sputter-coated with 4 nm of platinum-palladium in an atmosphere of argon. 
Scanning was then performed at ambient temperature and vacuum pressure. The mean 
microsphere diameter was quantitatively determined by measuring ~550 microspheres 
from the SEM micrographs using the Scion Image Analysis software. The pixel to 
distance ratio for each micrograph was entered into the software, and the edges of the 
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spheres were specified by hand. The number of microspheres (~550) measured for each 
stirring speed was sufficient to provide an accurate average (Table 2.1). 
 
2.3. Theory of Droplet Formation 
The following briefly reviews the basic principles of emulsification and droplet 
formation. A substantial literature of experimental, theoretical, and numerical work that 
discusses the mechanism of droplet breakdown is available [69,70]. Addition of 
Dichloromethane/PLG solution to the PVA solution forms an emulsion in which PLG is 
the dispersed phase and PVA is the continuous phase. Emulsion coalescence occurs 
when dispersed droplets collide with each other. Because the volume fraction of the 
dispersed PLG solution is low (Φ = 0.05), the analysis here is limited to the case of 
emulsion dispersion in turbulent flow under non-coalescing conditions. 
We next consider an isolated droplet and analyze the forces that lead to its breakup. 
As agitation is started, an external inertial stress (τ) acts on the droplet to cause its 
deformation. The inertial stress results from a dynamic pressure associated with the 
surrounding continuous phase. As the droplet starts to deform, internal restoring forces 
(viscous or surface tension) resist the deformation. The interfacial tension stress has 
magnitude σ/d where σ is the interfacial tension and d is the droplet diameter. Viscous 
stresses within the droplet are of the order of magnitude:
d
d
d ρ
τµ , where µd and ρd are 
the viscosity and density of the droplet respectively. A stable droplet is formed when a  
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Table 2.1 Measured volume moment mean diameter of PLG microspheres at different Wem 
Speed  
(rpm) 
Mixing Tank Weber 
Number (Wem) 
Mean Diameter 
a 
d43 ( µm) 
300 
600 
900 
1200 
76949 
307796 
692541 
1231185 
52.64 ± 0.8 
24.83 ± 0.4 
16.20 ± 0.2 
13.30 ± 0.2 
 
a
 Mean diameter ± standard error 
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balance between these three forces, dynamic pressure, internal viscous stress and surface 
tension, is reached [69]. 
Accordingly, two independent non-dimensional numbers can be obtained from 
dimensional analysis. The first non-dimensional number is a viscosity group that 
accounts for the effect of the viscosity of the fluid in the droplet: 
 
d
N
d
d
Vi
σρ
µ
=                                                                (2.1)                                               
 
Here we consider the case of a non-viscous dispersed phase where the viscous stress 
within the droplet is negligible compared with the interfacial tension at the droplet-water 
interface (i.e. NVi  0) [69]. 
The second non-dimensional number is the ratio of the dynamic pressure to the 
interfacial stress which results in the non-dimensional Weber number: 
 
στ /dNWe =                                                                    (2.2) 
 
As the ratio of the inertial stresses (dynamic pressure) to the interfacial tension force 
increases (an increase in Weber number), the deformation of the droplet increases to a 
point when a critical Weber number (NWe)crit is reached and breakup occurs. If the flow 
pattern is the same throughout the entire flow region, all droplets having a Weber 
number greater than (NWe)crit will be subject to break up.  
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Of significance here is the smallest eddy length scale (η), commonly referred to as 
the Kolmogorovs’ length scale ( 4/1
3
)(
ε
ν
η = , where ε is the rate of energy dissipation and ν 
is the kinematic viscosity), and the largest eddy scale L. For drop breakup in the inertial 
sub-range (η<< d <<L), the external viscous shear stresses are generally assumed 
negligible relative to the turbulent dynamic pressure forces [69]. Dynamic pressure 
forces are associated with changes in velocity over distances equal to the diameter of the 
droplet. Thus the turbulent stresses (τ) across a droplet can be expressed as 2vcρ , where 
2v  is the average value across the whole flow field of the square of the velocity 
difference across the droplet [69,70]. As a consequence, the critical Weber number can 
be expressed as: 
 
σ
ρ max
2
)(
dv
N ccritWe =                                                          (2.3)                                                          
 
where dmax is the diameter of the largest droplet that can resist breakup.  For the case of 
isotropic turbulence [69,71]: 
 
3/2
max
2 )( dcv ε=                                                        (2.4)                                                              
 
Thus 
            
σ
ερ 3/5max
3/2
)(
dc
N ccritWe =                                              (2.5) 
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Assuming that v (velocity difference across the droplet) is proportional to ND (where N 
is the stirring speed in radians per second, and D is the impeller diameter in meters) and 
the turbulence in the tank to be isotropic and fully developed, the turbulence energy 
dissipation, ε, can be shown to be proportional to N
3
D
2
 [70,72]:  
 
5/3
1
5/3
32
1
max )(
−− == m
c Wec
DN
c
D
d
σ
ρ
                                 (2.6) 
 
where Wem is called the Weber number of the mixing tank, and c1 is a constant to be 
uniquely determined for different emulsions [69,70]. 
The next step is to relate the maximum droplet diameter (dmax) to the mean droplet 
diameter. The general expression for mean diameters is: 
 
)/(1 hg
h
ii
g
ii
gh
dn
dn
d
−








=
∑
∑
                                                          (2.7) 
 
where g and h take values that correspond to the phenomena being investigated, ni is the 
number of droplets in size range i, and di is the diameter at the center of size range i. The 
Sauter mean diameter (d32) is the diameter of a drop whose ratio of volume to surface 
area is the same as that of the entire population: 
 
∑
∑=
2
3
32
ii
ii
dn
dn
d                                                                 (2.8) 
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Alternatively, the volume moment mean diameter (d43), which is of interest for 
controlled drug delivery, is the center of gravity of the volume fraction size distribution:  
 
         
∑
∑=
3
4
43
ii
ii
dn
dn
d                                                               (2.9) 
 
The Sauter mean diameter (d32) has generally been assumed to be proportional to the 
maximum sphere diameter (dmax) [70]. However, the generality of this assumption has 
been questioned in recent work by Pacek et al. [73]. Since the drop size distribution is 
universal, all representative diameters are uniquely related, so d43 is also taken to be 
proportional to dmax: 
 
   
5/3
2
43 −= mWec
D
d
                                                    (2.10)   
 
 
                                                                                
The main objective here is to evaluate c2 for PLG microspheres, and investigate how 
closely the correlation (2.10) predicts PLG microsphere mean diameter at different 
operating parameters.  
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2.4. Results and Discussion 
2.4.1. Microsphere Size Distributions 
To validate the theory presented in the previous Section, several batches of PLG 
microspheres were prepared over a wide range of stirring speeds. PLG microspheres 
were prepared according to the protocol described above, and a Caframo stirring paddle 
with a pitched–blade impeller was used with an impeller blade diameter of 5.8 cm. For 
consistency, the impeller was positioned in the center of the Pyrex beaker, half-way 
between the top surface of the PVA continuous phase and the bottom of the flask. In our 
experiment, the PLG/dichloromethane solution is the dispersed phase while the PVA 
solution is the continuous phase. As the stirring speed increased, more air was entrained 
and foam was formed. To avoid excessive foaming, antifoam of silicone and non-silicon 
constituents was used (0.1% v/v) that served to increase the rate at which air bubbles 
were dissipated. An aluminum foil lid was also used to seal the top of the beaker to 
reduce air entrainment. This was necessary as the entrained bubbles can damp turbulence 
intensity and affect the size of the microspheres [70]. 
To study the effect of Wem on the mean diameter of the microspheres formed, PLG 
microspheres were prepared at different stirring speeds (300-1200 rpm). For 
microspheres prepared at each stirring speed, the mean diameter was quantitatively 
determined by measuring the size of ~ 550 microspheres giving a small error for the 
mean diameter (Table 2.1). 
Figure 2.2 shows SEM micrographs of PLG microspheres prepared at: (a) N = 300 
rpm, (b) N = 600 rpm, (c) N = 900 rpm, and (d) N = 1200 rpm. Figure 2.3 shows the 
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corresponding cumulative volume fraction distributions, plotted against the diameter of 
PLG microspheres. When characterizing microspheres, the volume fraction of a 
specified range is significant because it indicates the mass distribution of microspheres 
at different diameters. This is required for calculating release kinetics for a population of 
microspheres. From inspection of the micrographs, it is apparent that the microspheres 
appear rigid and nicely spherical (Figure 2.2). It is also evident from the micrographs 
and the size distributions (Figure 2.3) that the microspheres are polydisperse, in some 
cases having microsphere diameters ranging from 6 to 92 µm (Figure 2.3 (a)). As 
expected from turbulent dispersion theory, Figure 2.2 and Figure 2.3 show a decrease in 
microsphere diameter with an increase in stirring speed. At 300 rpm (Figure 2.3 (a)), the 
microspheres span a wide range of diameters from 6 to 92 µm, this is also apparent in 
Figure 2.2 (a). As the stirring speed is increased to 600 rpm, the range of microsphere 
diameters is reduced to 7 to 43 µm (Figure 2.3 (b)). A further increase in the stirring 
speed to 900 rpm results in the microsphere diameter range being distributed from 4 to 
22 µm (Figure 2.3 (c)). Further increase in impeller speed to 1200 rpm has a weak effect 
on the distribution as can be seen in Figure 2.3 (d) where the majority of the spheres 
have a diameter that ranges from 3 to 20 µm. 
 
2.4.2. Mathematical Distribution Function 
A number of functions have been proposed, based on either probability or empirical 
considerations, that allow the mathematical representation of measured microsphere size  
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(a) N = 300 rpm                                                     (b) N = 600 rpm 
               
(c) N = 900 rpm                                                     (d) N = 1200 rpm  
Figure 2.2 SEM micrographs of PLG microspheres prepared at (a) N = 300 rpm, (b) N = 600 rpm, 
(c) N = 900 rpm, and (d) N = 1200 rpm. 
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(b) 
(a) 
   
Figure 2.3 Cumulative volume distribution at different impeller speeds, (a) 300 rpm, (b) 600 rpm, (c) 
900 rpm, and (d) 1200 rpm. 
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(c) 
(d) 
 
Figure 2.3 Continued 
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distributions. Those used include: normal, log-normal, Nukiyama-Tanasawa, and Rosin 
Rammler distributions [74]. After some trial and error the Rosin-Rammler distribution 
function provided the best representation of our experimental data. The volume fraction 
distribution function can be expressed in the following form: 
 
))(exp()()()
1
( )1( bbV
tot a
d
a
d
a
b
df
dd
dV
V
−== −                               (2.11) 
 
where Vtot is the total volume of the microsphere population, d is the droplet diameter, 
and a and b are constants to be obtained from a least squares fit to the volume fraction 
data. The Rosin-Rammler relationship describes drop size distribution in terms of the 
parameters a and b. For most distributions, b lies between 1.5 and 4. Integration of the 
volume fraction distribution function (Equation 2.11) yields the cumulative volume 
distribution function expressed as: 
 
))(exp(1)( bV
tot a
d
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V
V
−−==                                            (2.12)                       
 
where V is the total volume contained in drops of diameter less than d. As depicted in 
Figure 2.3, the cumulative Rosin-Rammler distribution function provides a good fit to 
the cumulative volume fraction distributions of PLG microspheres prepared using our 
experimental set-up. Corresponding values of a and b are given in Table 2.2. 
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Table 2.2 Coefficients of Rosin-Rammler mathematical function obtained through least squares fit 
to the volume fraction data at different Wem 
Speed 
(rpm) 
Mixing tank 
Weber number (Wem) 
a b 
300 
600 
900 
1200 
76949.1 
307796.2 
692541.5 
1231184.8 
58.15 
26.54 
18.65 
16.13 
3.15 
3.21 
4.52 
3.42 
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2.4.3. Microsphere Mean Diameters 
The correlation of Equation (2.10) predicts the mean diameter of microspheres 
formed as a function of Wem and D. In this Section the validity of this correlation is 
tested by comparing analytical predictions with experimentally obtained mean 
microsphere diameters at four different stirring speeds. Wem is calculated from Equation 
(2.6), using the density of PVA, impeller diameter, stirring speed in rpm, and interfacial 
tension at the water/dichloromethane interface [75-77]. 
Measured volume moment mean diameter (d43) of PLG microspheres prepared at 
different Weber numbers are given in Table 2.1, and Figure 2.4 shows a comparison 
between these measured mean diameters and the predicted mean diameters (given by 
Equation (2.10)) on logarithmic scale. The value of the coefficient c2 = 0.88, was 
obtained from a least squares fit to the experimental data. It is evident from Figure 2.4 
that the developed mathematical correlation provides a close fit to the experimental 
mean diameters over a wide range of Weber numbers. 
 
2.5. Conclusions 
PLG microspheres have been prepared using an emulsion technique, and a 
quantitative study has been performed on the resultant microsphere size distributions. A 
fluid mechanics based mathematical correlation for the mean microsphere diameter was 
developed based on the turbulent dispersion theory. The correlation, is given in Equation 
(2.10) with c2 = 0.88, and was validated by comparisons with experimental results for a  
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Figure 2.4 Volume moment mean diameter (d43) of PLG microspheres as a function of Wem on 
logarithmic scale; error bars represent interval estimate of population mean diameter with 99% 
level of confidence. 
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wide range of Wem. This correlation is valid for non-coalescing dispersions, with the 
dispersed phase having low viscosity, and volume fraction. The size distribution of PLG 
microspheres was described by a Rosin-Rammler distribution function that provided a 
close fit to the experimental data. This quantitative study makes possible an estimate of 
the mean size and size distribution of PLG microspheres prepared using the emulsion 
technique. In particular, the known size distribution is suitable for design of controlled 
release drug delivery systems. 
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3. EFFECT OF MICROSPHERE SIZE ON DRUG RELEASE* 3 
3.1. Background 
Difficulty achieving desired release rates is an important limitation in controlled drug 
delivery. Microsphere size, which has a significant effect on drug release rate, can 
potentially be varied to design a controlled drug delivery system with desired release 
profile. Mathematical modeling provides insight into the fundamental processes that 
govern the release, and once validated with experimental results, it can be used to tailor a 
controlled drug delivery system with specified drug release profile. Even though the 
majority of the conventional manufacturing techniques used for controlled drug delivery 
result in polydisperse microspheres, the mean diameter is used to represent the size of 
the microspheres when modeling drug release. As a consequence, the model does not 
account for the effect of population polydispersity which is believed to be one of the 
main causes for the initial drug “burst” release [78].  
To minimize the polydispersity effect on release kinetics, some investigators used 
manufacturing techniques that result in monodisperse populations, while others used 
sieves to fractionate the microspheres into more uniform size distributions. Berkland et 
al. [67] developed a method to produce microspheres of a monodisperse size distribution 
by spraying a polymer-containing solution through a nozzle. The nozzle was equipped 
with acoustic excitation and a non-solvent carrier stream to produce uniform droplets. 
                                                 
*Part of the data reported in this section is published in Int. J. Pharmaceut., 
doi:10.1016/j.ijpharm.2006.12.037, N.S. Berchane, K.H. Carson, A.C. Rice-Ficht, and M.J. Andrews, 
Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory.  
Copyright Elsevier (2007). 
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This technology was later used to produce monodisperse PLG microspheres to 
investigate the effect of microsphere size and polymer molecular weight on drug release 
[23,79]. Siepmann et al. [24] investigated the effect of the size of biodegradable 
microparticles on release rate of dispersed drug (monolithic dispersions). The 
manufacturing technique resulted in microspheres with a wide size distribution, and five 
different size fractions were then obtained by sieving [24]. Alternatively, Bezemer et al. 
[22] studied the release of protein from amphilic multiblock copolymers, based on 
hydrophilic poly(ethylene glycol) (PEG) blocks and hydrophobic poly(butylenes 
terephthalate) (PBT) blocks. Despite the wide microsphere size distribution, the effect of 
microsphere size was only represented in terms of the mean diameter [22].             
In this Section the effects of microspheres mean diameter, polydispersity, and 
polymer degradation on drug release rate from poly(lactide-co-glycolide) (PLG) 
microspheres are investigated experimentally. Based on the experimental results, a 
mathematical model is proposed that accounts for the effects of diffusion, polymer 
degradation, and microsphere size distribution to predict drug release kinetics from 
polydisperse PLG microsphere populations.  
 
3.2. Materials and Methods 
3.2.1. Materials 
The poly(D,L-lactide-co-glycolide) used had a copolymer composition of 50:50, a 
Mw of ~ 40 kDa, and is a product of Sigma. The Poly (vinyl-alcohol) (PVA) was 87%-
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89% hydrolyzed, with a Mw of 13 – 23 kDa. In addition to these chemicals, Piroxicam 
(Mw 331.3), and HPLC grade Dichloromethane (DCM) were purchased from Sigma. 
Sodium hydroxide was purchased from EM Science. All chemicals were used as 
provided. 
 
3.2.2. Microsphere Preparation 
PLG microspheres were prepared using the oil-in-water (o-w) emulsion solvent 
extraction technique described previously (Section 2.2.2, Figure 2.1). Briefly, Piroxicam 
was co-dissolved with PLG (10% w/v) in dichloromethane (DCM) at 20% of the PLG 
mass (20% theoretical loading (w/w)). PVA solution (8% w/v) was stirred at the desired 
stirring speed for 5 minutes in a 400 ml Pyrex beaker with a Caframo ultra high torque 
stirrer (model BDC1850) having a speed range of 0 -1800 rpm. The PLG solution was 
slowly added to the beaker and stirring was continued for 60 minutes. Afterwards, the 
resulting emulsion was added to 1L of double distilled water, and stirring was continued 
for an additional 90 minutes at a speed of 1200 rpm. Microspheres were then collected 
by filtration, where the filter size used was 0.2 µm to prevent any loss of microspheres. 
 Three batches of microspheres were prepared at three different impeller speeds (140, 
300 and 900 rpm) to produce microspheres having a wide size distribution (0.2 - 140 
µm). The correlation developed by Berchane et al. [80], which relates PLG microsphere 
population mean diameter to impeller speed, was utilized to determine the impeller 
speeds that would result in the desired microsphere sizes. A portion of the microspheres, 
prepared at different impeller speeds, was stored for drug release investigations from raw 
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batches, while the rest of the microspheres were combined and sieved to obtain five 
different size fractions: 0.2 - 20, 20 - 40, 40 - 63, 63 - 90, and > 90 µm (average pore 
sizes of the sieves: 20, 40, 63, and 90 µm; Keison Products, United Kingdom). Once 
sieved, the microspheres were lyophilized and stored at -20˚C.  
 
3.2.3. Determination of Piroxicam Loading 
The experimental loading of piroxicam was determined by dissolving 2 mg of 
microspheres in 1 ml of 0.25 M sodium hydroxide at 37 ºC for 48 hours. Piroxicam has 
been shown to be stable in sodium hydroxide solution [81], and is thus believed to be 
stable under extraction. Piroxicam free microspheres of the same molecular weight were 
treated similarly. Drug concentration was determined by measuring the absorbance of 
the piroxicam containing solution in a quartz cuvette at 276 nm (Gilford Response 
Spectrophotometer) and subtracting the absorbance of the piroxicam free solution. The 
experiments were done in triplicate.   
 
3.2.4. In Vitro Release 
Drug release was determined by suspending 5 mg of piroxicam loaded microspheres 
in 1.3 ml of phosphate buffered saline (PBS, pH 7.4). Piroxicam maintains an unchanged 
structure in buffer media [82], and is thus believed to be stable under the in vitro release 
conditions. The suspension was continuously agitated by shaking (Glas-Col, Terre 
Haute, USA) at 100 strokes per minute in a 37 ºC incubator. At predetermined intervals, 
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the samples were centrifuged, and 1 ml of the supernatant was extracted, and replaced by 
fresh buffer. The microspheres were then vortexed and put back into the incubator. 
Resuspending the microspheres in fresh buffer after centrifugation (by vortexing), and 
continuous agitation of the suspension throughout the release experiment prohibited 
microsphere aggregation and sedimentation. The piroxicam concentration in the 
supernatant was determined by measuring the absorbance at 276 nm in a 
spectrophotometer (Gilford Response Spectrophotometer). Drug concentration was less 
than 10% of the saturation solubility in the release medium at 37 ºC, which conforms to 
sink conditions [83]. Piroxicam-free microspheres were treated similarly, and the 
absorbance from their supernatant was subtracted from all measurements. The 
experiments were done in triplicate.    
 
3.2.5. Microsphere Characterization 
Imaging of microspheres was performed with a LEO-VP1530 field emission 
scanning electron microscope as described in Section 2.2.3. The mean diameter was 
quantitatively determined by measuring ~1000 microspheres from the SEM micrographs 
using the Scion Image Analysis software. The pixel to distance ratio for each micrograph 
was entered into the software, and the edges of the spheres were specified by hand. The 
number of microspheres (~1000) measured for each population was sufficient to provide 
an accurate mean diameter (Table 3.1).  
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Table 3.1 Characterization of sieved and raw piroxicam loaded PLG microspheres 
Microsphere 
population 
Mean diameter
a
  
d43 (µm) 
a b 
Theoretical drug 
loading (% w/w) 
Experimental drug 
loading (% w/w) 
Encapsulation 
efficiency (%) 
> 93        µm 
63 – 90   µm 
40 – 63   µm 
20 – 40   µm 
0.2 – 20  µm 
140 rpm 
300 rpm 
900 rpm 
- 
81.2 ± 0.4 
51.0 ± 0.4 
29.6 ± 0.3 
13.9 ± 0.2 
76.0 ± 0.9 
33.5 ± 0.4 
13.5 ± 0.2 
- 
80.5 
50.9 
29.6 
13.8 
75.3 
33.1 
13.3 
- 
9.7 
5.4 
6.0 
3.17 
3.78 
3.1 
2.7 
20 
20 
20 
20 
20 
20 
20 
20 
5.94 
5.33 
5.2 
4.7 
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3.3. Mathematical Model 
In diffusion-controlled drug release systems, a substance is released from a device by 
permeation from its interior to the surrounding. There are two main types of diffusion 
controlled systems, the reservoir system and the monolithic system [1]. In a reservoir 
system the active agent is enclosed by an inert outer membrane, while in monolithic 
systems the drug is dispersed uniformly through-out the rate controlling polymer matrix 
(Figure 1.2). If the active agent is dissolved in the polymer matrix, the device is called 
monolithic solution, while if the drug is dispersed as a solid, the system is called a 
monolithic dispersion [1]. In this work the microspheres were prepared by co-dissolving 
the polymer and the drug in DCM which results in a monolithic solution. 
Diffusion is the process by which matter is transported from one part of a system to 
another as a result of random molecular motions. The motion of a single molecule can be 
described in terms of the “random walk” in which no molecule has a preferred direction 
of motion. Although it is not possible to know in which direction any individual 
molecule will move in a given interval of time, there is a net transfer of molecules from 
regions of high concentration to regions of low concentration as a result of the random 
molecular motions [84]. Transfer of heat by conduction is also due to random molecular 
motions, and there is an analogy between the two processes. This was recognized by 
Fick [85] who adopted the mathematical equation of heat conduction derived by Fourier 
[86] to develop the mathematical theory of diffusion. The diffusion theory is based on 
the hypothesis that the rate of transfer of diffusing substance through unit area of a 
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Section is proportional to the concentration gradient measured normal to the Section 
[85]: 
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C
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where F is the diffusion flux in dimensions of [amount of substance length
-2
 time
-1
], 
example (gm/m
2
s), C is the concentration of the diffusing substance in dimensions of 
[amount of substance length
-3
], example (gm/m
3
), x is the space coordinate measured 
normal to the Section in dimensions of [length], example (m), and D is the diffusion 
coefficient in dimensions of [length
2 
time
-1
], example (m
2
/s) . The negative sign in 
Equation (3.1) arises because diffusion occurs in the direction opposite to that of 
increasing concentration [85].  
The fundamental differential equation of diffusion can be derived by considering an 
element volume in the form of a rectangle whose sides are parallel to the axes of the 
coordinates. By evaluating the rate at which diffusing substance enters the element 
volume through its faces, and the rate at which the amount of diffusing substance in the 
element increases, Fick [85] obtained the following expression for the diffusion 
equation: 
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where t is time. Expressions (3.1) and (3.2) are usually referred to as Fick’s first and 
second laws of diffusion respectively, since they were first formulated by Fick [85] 
through direct analogy with the equations of heat conduction. If the diffusion coefficient 
(D) is time dependent, then on introducing a new time-scale T such that [84]: 
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the diffusion equation becomes: 
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For diffusion in a sphere, Equation (3.4) can be expressed in spherical polar coordinates 
as [84]: 
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The simplified form of Equation (3.5) for purely radial diffusion in a spherically 
symmetrical system can be expressed as: 
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Solving the above equation for a sphere of specified diameter dm and radius R having a 
surface concentration maintained at zero (sink condition), and an initial uniform 
concentration, C1 [84]: 
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results in the following solution [84]: 
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The total amount of drug released from the sphere per unit time can be determined by 
evaluating Fick’s first law of diffusion (Equation (3.1) in polar coordinates) at the 
surface of the sphere (r = R), using equation 3.7. After integration and further 
mathematical manipulation, the following equation is obtained for the total amount of 
diffusing drug leaving a sphere of diameter dm [84]: 
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where 
md
t
M
M
)(
∞
 is the cumulative fraction of drug released from a sphere of diameter dm, 
at time t .  
The drug diffusion coefficient is time dependent due to bulk degradation of the 
polymer matrix. As the polymer molecular weight (Mw) decreases, the drug has more 
available space to diffuse through the polymer chains, and so the diffusion coefficient 
increases. The dependence of diffusion coefficient of piroxicam on PLG molecular 
weight was investigated by Raman et al. [79], and an empirical mathematical equation 
was obtained to represent this dependence: 
 
95.31695.104394.10347.0)ln( 23 +−+−= xxxD                              (3.9)                              
 
where x = ln(Mw). Initial drug burst release is well documented in the literature, and has 
been attributed to a variety of physical, chemical, and processing parameters, but for the 
most part, the underlying mechanism is not clearly understood [87]. To account for this 
initial burst release, an initial diffusivity (D0) is used as a fitting parameter. D0 is used 
until the time dependent diffusivity D(Mw) is larger than D0.  
Hydrolysis, which causes bulk degradation of PLG polymer, starts with water 
uptake. The first stage of the process is confined to a decrease in the molecular weight 
caused by random hydrolytic ester cleavage, while the second stage is characterized by 
the onset of weight loss. The first stage of the degradation process is expressed as [13]: 
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where Mw(t) is the molecular weight of the polymer at time t, Mw(0) is the molecular 
weight of the polymer at time t = 0, and kdeg is the polymer degradation constant. The 
rate of polymer degradation, represented by the degradation constant (kdeg), is dependent 
on the hydrolysis mechanism taking place. PLG degradation has been widely 
investigated [24,79,88-91], and values for kdeg reported in the literature range from 
0.0638 1−d  to 0.104 1−d . Other degradation studies performed on PLG microspheres 
have shown dependence of polymer degradation constant (kdeg) on microsphere diameter 
[78]. It is believed that large microspheres degrade more quickly than small 
microspheres because of an increased buildup of the acidic byproducts of polymer 
hydrolysis in large microspheres [78]. In addition, drug release can occur by diffusion 
through pores formed as a result of polymer erosion which results in higher effective 
diffusivities than those predicted solely by polymer bulk degradation. In this work the 
degradation constant, kdeg, is used as a fitting parameter, and the obtained values are 
compared with the reported data in the literature.  
 
3.3.1. Modeling Size Distribution 
This work considers the release from a microsphere population of non-uniform size 
distribution. The non-dimensional cumulative mass release equation for a polydisperse 
microsphere population can be expressed as: 
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where 
∞M
M t  is the cumulative fraction of drug released from the population at time t, dmin 
and dmax are the diameters of the smallest and largest microspheres in the population 
respectively, g(dm) represents the size distribution of the population, and 
md
t
M
M
)(
∞
 is the 
cumulative fraction of drug released from a sphere of diameter dm, at time t , evaluated 
using Equation (3.8). When characterizing microspheres for drug release studies, the 
mass fraction size distribution is used which represents the mass of microspheres in a 
specific size interval divided by the total mass of the population and the length of the 
size interval. Since the density of the microspheres is not a function of microsphere size, 
the mass fraction size distribution and the volume fraction size distribution are 
equivalent, and are thus used interchangeably. It was shown in previous work by 
Berchane et al. [80] that the Rosin-Rammler mathematical distribution function provides 
an accurate representation of the size distributions of PLG microspheres prepared using 
our experimental set-up. For constant drug loading throughout the entire population 
(Table 3.1), the Rosin-Rammler function also represents the drug mass distribution for 
the population. The Rosin-Rammler distribution function can be expressed in the 
following form [74,80]: 
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where dm is the microsphere diameter, a and b
 
are constants to be obtained from a least 
squares fit to the experimentally measured size distributions of PLG microspheres. 
Alternatively, the microsphere population size distribution can be accounted for in 
the mathematical model using the representative mean diameter, and then Equation 
(3.11) is reduced to Equation (3.8). In this work the mean diameter calculated is the 
mass/volume moment mean diameter (d43), also known as De Brouckere mean diameter, 
which is the center of gravity of the mass/volume fraction size distribution. 
 
3.3.2. Numerical Solution of Model Equations 
A Matlab program was written to implement the mathematical theory developed in 
this Section. To determine the accuracy in approximating the infinite series in Equation 
(3.8), we use the concept of remainder [92]: 
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where aj represent the terms of the infinite series, S is the exact value of the series, SJ is 
the approximate value of the series using its first J terms, and RJ is the remainder. 
Inspection of Equation (3.13 e) reveals that the terms of the infinite series have the 
largest values at T = 0 when the decaying exponential term is equal to unity. As a 
consequence, the largest value of RJ occurs at T = 0:  
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A series of the form ∑ ∞==
j
j pj1
1
 is called a p-series and has a remainder
1
1
−
<
−
p
J
R
p
J  , which 
reduces to 
J
RJ
1
<  for p = 2 [92]. Then the infinite series in Equation (3.13) has a 
remainder
J
RJ 2
6
π
< , and Figure 3.1 plots the maximum value of RJ as a function of J. 
Here we use the hundredth partial sum to approximate the infinite series which results in 
RJ < 0.006.   
The integral in Equation (3.8) was evaluated numerically over the interval [0,t]. This 
is achieved by dividing the interval [0,t] into n uniformly spaced subintervals of length h 
(h = t/n), and then sampling with a set of discrete points {t0 , t1 , … , tn} where t0 = 0, and 
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Figure 3.1 Maximum error in approximating the infinite series by its fist J terms. 
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 tn = t. The trapezoid rule was then used, which estimates the area beneath the curve 
using trapezoids [93]:  
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Since the trapezoids only approximate the integrand D(t), there is a truncation error 
which decreases as the step length (h) decreases [93]: 
 
DthError ′′= 2
12
1
                                              (3.16) 
 
where t is time, h is the step length, and  D ′′ represents the average value of the second 
derivative of D(t) over the n intervals. The largest error in approximating the integral 
occurs at late time when the value of D ′′  exhibits a sharp increase. In this work a step 
length of 1 hr was used for evaluating the integral in Equation (3.8), which results in a 
maximum error < 1% when determining T(t). 
 
3.4.  Results and Discussion 
3.4.1. Microsphere Fabrication and Characterization 
To investigate the effect of microsphere size on drug release rate, three batches of 
PLG microspheres were prepared at different impeller speeds (140, 300, and 900 rpm). 
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A portion of the microspheres was removed from each batch, and then the different 
portions were added together and sieved which resulted in five different size fractions 
(0.2 – 20; 20 – 40; 40 – 63; 63 – 90; and >90 µm). SEM micrographs of the sieved and 
raw microspheres are shown in Figure 3.2 and Figure 3.3 respectively. The volume 
fraction size distribution is used when characterizing microspheres for drug release 
studies. This size distribution represents the mass of microspheres in a specific size 
interval divided by the total mass of the population and the length of the size interval. 
Figure 3.4 and Figure 3.5 show the corresponding volume fraction distributions, plotted 
against the diameter of PLG microspheres. From inspection of the micrographs in Figure 
3.2 and Figure 3.3, it is apparent that the microspheres appear rigid and nicely spherical 
with a smooth surface. It is also evident from the micrographs and the size distributions 
that the majority of the fractionated microspheres lie within the mean pore diameter of 
the sieves used, except for some very small microspheres trapped with the large 
microspheres (Figure 3.2, and Figure 3.4). Although these small microspheres are large 
in number (as can be seen from the micrographs), the size distributions show that their 
volume fraction is negligible and as a result does not have an effect on the release 
profile.   
 The Rosin-Rammler Distribution function was shown by Berchane et al. [80] to give 
the best representation of the volume fraction experimental data. This function is 
expressed in the following form [74]: 
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Figure 3.2 SEM micrographs of sieved piroxicam loaded PLG microspheres: (a) > 90 µm, (b) 63 – 90 
µm, (c) 40 – 63 µm, (d) 20 – 40 µm, and (e) 0.2 – 20 µm. 
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Figure 3.3 SEM micrographs of raw piroxicam loaded PLG microspheres: (a) N = 140 rpm, (b) N = 
300 rpm, and (c) N = 900 rpm. 
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Figure 3.4 Volume fraction distributions of sieved piroxicam loaded PLG microspheres: (a) 63 – 90 
µm, (b) 40 – 63 µm, (c) 20 – 40 µm, and (d) 0.2 – 20 µm.  
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 Figure 3.4 Continued 
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Figure 3.5 Volume fraction distributions of raw piroxicam loaded PLG microspheres: (a) N = 140 
rpm, (b) N = 300 rpm, and (c) N = 900 rpm.  
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Figure 3.5 Continued 
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where Vtot is the total volume of the microsphere population, dm is the microsphere 
diameter. The Rosin-Rammler relationship describes microsphere size distribution in 
terms of the parameters a and b, where a provides a measure of the distribution mean 
diameter, while b provides a measure of the spread of the microsphere sizes. If b is 
infinite, the microspheres are all of the same size, and as the value of b decreases, the 
spread of the microspheres increases [74]. Integration of the volume fraction distribution 
function (Equation (3.17)) yields the cumulative volume distribution function expressed 
as:  
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where V is total volume contained in microspheres of diameter less than dm. The 
parameters a and b are obtained from a least squares fit of the Rosin-Rammler 
cumulative volume distribution function (Equation (3.18)) to the experimental 
cumulative volume fraction distributions (Figure 3.6). The values for a and b are given 
in Table 3.1. The parameter b, which provides a measure of polydispersity, ranges from 
2.7 to 3.78 for raw populations and from 3.17 to 9.7 for sieved populations (Table 3.1).  
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(a) 
 
Figure 3.6 Cumulative volume fraction distributions of (a) sieved and (b) raw, piroxicam loaded 
PLG microspheres. 
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(b) 
 
Figure 3.6 Continued 
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This shows that sieving was effective in reducing the polydispersity of the microsphere 
populations, and is important because one of the objectives of this work was to fabricate 
microsphere populations of varying polydispersity to investigate the effect of 
polydispersity on drug release rate. 
 
3.4.2. In Vitro Drug Release Kinetics   
Figure 3.7 shows experimentally measured in vitro release of sieved piroxicam 
loaded PLG microspheres having different size fractions. The release profiles shown in 
the figures are normalized to the total amount of drug released at the end of the study, 
which was within 10% of the experimental loading shown in Table 3.1. The mean 
diameters (d43) of the microspheres range from 13.9 to 81.2 µm (Table 3.1). Inspection 
of Figure 3.7 reveals that size is a major determinant of the release profile, and drug 
initial release rate decreased with increasing microsphere size. This is consistent with 
Fick’s law of diffusion which attributes this decrease in drug release rate to an increase 
of diffusion pathways (reduced surface area to volume ratio for large spheres). In 
addition, microsphere populations having a mean diameter of 29.6 µm and above exhibit 
concave-upward (i.e sigmoidal) profile, with a high initial rate of drug release (“burst 
release”) which then slows down before it progresses again into a more rapid release 
phase before leveling off. This sigmoidal profile is most obvious for populations with 
large mean diameters (d43 > 51.0, Figure 3.7 (a)-(c)), and to a lesser extent in the 29.6 
µm mean diameter population (Figure 3.7 (d)), which exhibits a near constant release         
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Figure 3.7 Experimental drug release profile of sieved PLG microspheres: (a) > 90 µm, (b) 63 – 90 
µm, (c) 40 – 63 µm, (d) 20 – 40 µm, and (e) 0.2 – 20 µm. 
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Figure 3.7 Continued 
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Figure 3.7 Continued 
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(near zero-order profile). Although the initial burst release has been reported in 
numerous publications in our field, knowledge about the underlying mechanism is 
limited. One potential explanation for this burst release is that some drug becomes 
trapped on the surface of the polymer matrix during the manufacturing process [87]. The 
sigmoidal shape is believed to be a result of polymer degradation. As the polymer 
degrades, its molecular weight decreases, which causes an increase of the diffusion 
coefficient of the drug through the polymer matrix. This is translated into an increase in 
the drug release rate which gives rise to the sigmoidal profile. The 13.9 µm population 
(our smallest), and contrary to the other populations, exhibits first order release (Figure 
3.7 (e)). It is believed that this is a result of the rapid initial rate of release with ~ 50% of 
encapsulated drug released within the first 3 days, during which polymer degradation 
effects are still negligible. In addition, polymer degradation proceeds at a slower rate for 
smaller microspheres [78].      
Figure 3.8 shows the release from raw microsphere populations prepared at 3 
different speeds (140, 300, 900 rpm). The mean diameters of the microspheres range 
from 13.5 to 76 µm (Table 3.1). The drug release profiles from raw populations exhibit 
the same behavior as those from sieved populations having comparable mean diameters. 
Microspheres prepared at 140, and 300 rpm (having mean diameters of 76.0 and 33.5 
µm respectively) have concave- upward (i.e. sigmoidal) profile, while microspheres 
prepared at 900 rpm (13.5 µm mean diameter) exhibit first order release.    
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Figure 3.8 Effect of microsphere size on piroxicam release for raw microspheres. 
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3.4.3. Model Results  
A Matlab program was written to solve the derived cumulative release equations 
(Equations (3.8) and (3.11)), with a time dependent diffusivity and two fitting parameters 
(D0 and kdeg), to predict the release of piroxicam from PLG microspheres having 
different mean diameters and size distributions. Dependence of diffusivity on molecular 
weight was modeled using Equation (3.9). To account for the initial burst release, an 
initial diffusivity (D0) is used as a fitting parameter. D0 is used until the time dependent 
diffusivity D(Mw) is larger than D0.  
Since the molecular weight of PLG polymer varies with time, it was modeled using 
Equation (3.10). The rate of polymer degradation, represented by the degradation 
constant (kdeg), is dependent on the hydrolysis mechanism taking place. PLG degradation 
has been widely investigated [24,79,88-91], and reported values for kdeg range from 
0.0638 d
-1
 to 0.104 d
-1
. Here kdeg is used as a fitting parameter, and the obtained values 
are compared with the reported data in the literature.     
Size distribution of the microspheres was represented in the mathematical model in 
two different approaches to investigate the use of the population size distribution model, 
and the alternative mean diameter model. For accurate modeling of the drug release 
profile, the size distribution of the populations was incorporated into the model, and 
Equation (3.11) was solved. Alternatively, Equation (3.8) was solved which utilizes the 
volume moment mean diameter to represent the size distribution of the population. As 
mentioned previously, the volume moment mean diameter is the center of gravity of the 
volume fraction size distribution. The aim was to investigate the effect of polydispersity 
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on drug release rate. Figure 3.9 and Figure 3.10 show the release profiles generated by 
the model compared with the experimental drug release data for sieved and raw 
microsphere populations respectively. The solid lines represent modeling results based 
on size distribution, while dashed lines represent modeling results based on mean 
diameter. It is evident from Figure 3.9 and Figure 3.10 that the model based on size 
distribution is in good agreement with all the experimental results, and that the deviation 
of the mean diameter based model from experimental results increases as the 
polydispersity of the population increases. Here we use the value of the parameter b 
(Table 3.1), obtained by curve fitting the cumulative Rosin-Rammler function to the 
experimental cumulative volume fraction distributions, to represent the degree of 
polydispersity of the populations. For populations having a value of b close to or less 
than 3.0 (0.2 -20 µm, 300, and 900 rpm in Table 3.1), the deviation is considerable 
(Figure 3.9 (d), Figure 3.10 (b),(c)), R
2 
< 0.974). Alternatively, populations that have a 
value of b equal to 3.78 and above (20 – 40, 40 – 63 and 63 – 90 µm, 140 rpm, in Table 
3.1), the deviation is negligible (Figure 3.9 (a-c) Figure 3.10 (a), R
2 
> 0.994). Thus, for 
populations having a value of b value ~ 3, the effect of polydispersity on drug release is 
significant, and as a result incorporating the size distribution of the population into the 
model is necessary to provide an adequate fit for practical use. Consequently, it is 
recommended that the size distribution be incorporated into the model, when working 
with populations which have a value of b equal to or less than 3.  
From Figure 3.9 and Figure 3.10, it can be observed that the degradation constant 
(kdeg), obtained by curve fitting, increased from 0.07 d
-1
 for the microsphere population  
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(a) 
(b) 
 
Figure 3.9 Comparison of model profiles to experimental results of sieved piroxicam loaded PLG 
microspheres: (a) 63 – 90 µm, (b) 40 – 63 µm, (c) 20 – 40 µm, and (d) 0.2 – 20 µm. 
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(c) 
(d) 
   
Figure 3.9 Continued 
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(a) 
(b) 
 
Figure 3.10 Comparison of model profiles to experimental results of raw piroxicam loaded PLG 
microspheres: (a) N = 140 rpm, (b) N = 300 rpm, and (c) N = 900 rpm. 
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(c) 
 
Figure 3.10 Continued 
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having a mean diameter of 13.5 µm (900 rpm population, Figure 3.10 (c)) to 0.088 d
-1 
for the microsphere population having a mean diameter of 81.2 µm (63 – 90 µm 
population, Figure 3.9 (a)). This is consistent with published work which report that 
large microspheres degrade faster than small microspheres because of an increased 
buildup of acidic byproducts [78]. In addition, the values for kdeg obtained in this work 
are in good agreement with data reported in the literature which range between 0.0638 
1−d  and 0.104 1−d  [24,79,88-91].  
It has been previously mentioned that an initial diffusivity (D0) is used in this work 
to account for the initial drug burst release. Although this burst release is well 
documented in the literature, the underlying mechanism is not clearly understood [87]. It 
has been hypothesized that polydispersity is one of the main causes for the initial drug 
burst release, due to the presence of small microspheres which encapsulate sufficient 
amount of drug that is released more rapidly [78]. Here we investigate this hypothesis by 
considering the release from the 63-90 µm sieved population (Figure 3.9 (a)). This 
population has a value of b equal to 9.7 (Table 3.1), which indicates negligible 
polydispersity effect on drug release. However, by inspecting Figure 3.9 (a), it is 
observed that this population has high initial rate of drug release with an initial 
diffusivity (D0, obtained by curve fitting the size distribution based mathematical model 
to the experimental results) equal to 10.0 ×  10-18 m2/sec. This value is significantly 
higher than the time dependent diffusivity, D(Mw), at time t = 0 (D(Mw(0)) = 1.7 ×  10
-18
 
m
2
/sec), which indicates that the diffusion model does not account for this initial burst 
release. Thus although this population has negligible polydispersity effect, it exhibits an 
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initial drug burst release that cannot be merely explained by the diffusion model. This 
leads us to the conclusion that polydispersity is not the main cause for this initial burst 
release. The same conclusion can be made from recent work published by Raman et al. 
[79], which investigated drug release rates from monodisperse PLG microspheres. 
Despite the uniformity of the microsphere populations, a high initial rate of drug release 
was observed which also cannot be explained by the diffusion model [79]. One potential 
explanation for the burst effect is that some drug becomes trapped on the surface of the 
polymer matrix during the manufacturing process [87]. 
 
3.5. Conclusions 
Piroxicam loaded PLG microspheres have been prepared using an emulsion 
technique. The effect of microsphere mean diameter, polydispersity, and polymer 
degradation on drug release rate from the microspheres was investigated. A 
mathematical model is reported that predicts drug release from polydisperse PLG 
microspheres. The model accounts for the effects of diffusion, polymer degradation and 
microsphere size distribution. It was shown that drug initial release rate decreased with 
an increase in microsphere size. Also, the release profile changed from first order to 
concave-upward as the microsphere size was increased. Polydispersity did not have a 
significant effect on drug release rate for populations having a polydispersity parameter 
(b) larger than 3. Alternatively, for distributions having a value of b close to or below 3, 
incorporating the size distribution of the population into the model provided a better fit 
to the experimental results. In addition it was shown that polydispersity was not the main 
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cause for the initial “burst” release. The model results were in good agreement with 
experimental results, and thus can be used to predict drug release from polydisperse 
populations of microspheres. 
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4. DESIGNING DRUG RELEASE PROFILES 
4.1. Background 
Rapid development in the field of molecular biology and biotechnology resulted in 
generation of numerous new drugs that treat a wide range of indications. The therapeutic 
potential of these compounds lies in our ability to design and achieve an effective and 
stable delivery system. The ideal drug release profile is one that initiates the optimum 
response in a patient such as zero-order release and pulsatile release [5,49-54]. Zero-
order release [49-51] is desired for a wide range of drugs because it maintains a constant 
level of drug concentration well within the therapeutic window for extended time 
periods. Pulsatile release [5,52-54] is attractive for vaccine delivery, as the drug release 
formulation can be designed to deliver distinct pulses which solves the need for booster 
shots. Difficulty in achieving the desired drug release rates (simple zero-order profile or 
more complex pulsatile release profile), remains to be one of the major challenges in 
controlled drug delivery. Different parameters have been employed to control the release 
rate from biodegradable PLG microspheres [10,23,24,79]. In addition to microsphere 
size [23,24], PLG molecular weight [79] and lactide glycolide ratio [10] play a 
significant role in controlling drug release kinetics. To gain further control over release 
rates, some researchers have combined individual microsphere preparations having 
different release profiles to achieve desired release kinetics [23,49]. Narayani and Rao 
[49] successfully obtained near constant release of anticancer drugs 5-fluorouracil (5-
Fu), and methotrexate (MTX) for 6 to 10 days by mixing drug loaded gelatin 
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microspheres of different size ranges. Similarly, Berkland et al. [23] mixed known ratios 
of rhodamine and piroxicam containing PLG microsphere populations having different 
mean diameters and drug loadings to attain zero-order release [23]. The ratios of the 
individual populations were determined by trial and error where multiple linear 
combinations were examined computationally to identify a combination resulting in 
linear drug release. It was found that the release profile from a mix of microsphere 
populations corresponded to mass-weighted linear combination of the individual release 
profiles, and constant release of rhodamine and piroxicam for 8 days and 13 days 
respectively was achieved [23].   
 In this Section, PLG microspheres having 2 different Mw and three different size 
fractions are prepared using the solvent extraction emulsion technique. The effect of 
microspheres mean diameter and polymer molecular weight, on drug release rate from 
poly(lactide-co-glycolide) (PLG) microspheres is investigated experimentally. The 
mathematical theory developed in the previous Section is used to model the effect of 
polymer molecular weight on drug release. A numerical optimization technique based on 
the least squares method is developed to achieve desired release profiles by combining 
appropriate proportions of individual microsphere populations. 
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4.2. Materials and Methods 
4.2.1. Materials 
Poly(D,L-lactide-co-glycolide) (PLG) polymer having a co-polymer composition of 
50:50, and two different Mw (18 kDa: inherent viscosity 0.41 dl/g, and 55 kDa: inherent 
viscosity 0.87 dl/g; inherent viscosity measured in hexaflouroisopropanol) was 
purchased from Birmingham Polymers. The Poly (vinyl-alcohol) (PVA) was 87%-89% 
hydrolyzed, with a Mw of 13 – 23 kDa. In addition to PVA, Piroxicam (Mw 331.3), and 
HPLC grade Dichloromethane (DCM) were purchased from Sigma. Sodium hydroxide 
was purchased from EM Science. All chemicals were used as provided. 
 
4.2.2. Microsphere Preparation 
PLG microspheres were prepared using a previously described method (Section 
2.2.2, Figure 2.1). Briefly, Piroxicam was co-dissolved with PLG (10% w/v) in 
dichloromethane (DCM) at 10% of the PLG mass (10% theoretical loading (w/w)). PVA 
solution (8% w/v) was stirred at the desired stirring speed for 5 minutes in a 400 ml 
Pyrex beaker with a Caframo ultra high torque stirrer (model BDC1850) having a speed 
range of 0 -1800 rpm. The PLG solution was slowly added to the beaker and stirring was 
continued for 60 minutes. Afterwards, the resulting emulsion was added to 1L of double 
distilled water, and stirring was continued for an additional 90 minutes at a speed of 
1200 rpm. Microspheres were then collected by filtration, where the filter size used was 
0.2 µm to prevent any loss of microspheres. 
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PLG microspheres having two different polymer molecular weights (18 kDa. and 55 
kDa) were prepared at different impeller speeds (Table 4.1). The correlation developed 
by Berchane et al. [80], which relates PLG microsphere population mean diameter to 
impeller speed, was utilized to determine the impeller speeds that would result in the 
desired microsphere sizes. Each microsphere preparation was then sieved separately 
using the appropriate sieve sizes (Table 4.1) to obtain three different size fractions for 
each polymer molecular weight: 0.2 - 20, 20 - 40, and 63 - 90 µm (average pore sizes of 
the sieves: 20, 40, 63, and 90 µm; Keison Products, United Kingdom). Once sieved, the 
microspheres were lyophilized and stored at -20˚C. 
 
4.2.3. Determination of Piroxicam Loading  
The experimental loading of piroxicam was determined by dissolving 2 mg of 
microspheres in 1 ml of 0.25 M sodium hydroxide. Piroxicam free microspheres having 
the same molecular weight were treated similarly. Drug concentration was determined by 
measuring the absorbance of the piroxicam containing solution in a quartz cuvette at 276 
nm (Gilford Response Spectrophotometer) and subtracting the absorbance of the 
piroxicam free solution.   
 
4.2.4. In Vitro Release 
Drug release was determined by suspending 5 mg of piroxicam loaded microspheres 
in 1.3 ml of phosphate buffered saline (PBS, pH 7.4). The suspension was continuously  
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Table 4.1 Characterization of piroxicam-loaded PLG microspheres 
Mw 
(kDa) 
Impeller 
Speed (rpm) 
Sieve Fraction 
(µm) 
Mean Diameter
a 
d43 (µm) 
Encapsulation 
Efficiency (%) 
18.0 
18.0 
18.0 
55.0 
55.0 
55.0 
150 
300 
900 
200 
400 
1200 
0.2-20 
20-40 
63-90 
0.2-20 
20-40 
40-63 
14.9 ± 0.3 
31.2 ± 0.3 
76.2 ± 0.7 
12.8 ± 0.2 
32.3 ± 0.3 
83.2 ± 0.7 
28.0 
23.6 
33.3 
26.0 
24.7 
24.6 
a
Mean diameter ± standard error 
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agitated by shaking (Glas-Col, Terre Haute, USA) at 100 strokes per minute in a 37 ºC 
incubator. At predetermined intervals, the samples were centrifuged, and 1 ml of the 
supernatant was extracted, and replaced by fresh buffer. The microspheres were then 
vortexed and put back into the incubator. The piroxicam concentration in the supernatant 
was determined by measuring the absorbance at 276 nm in a spectrophotometer (Gilford 
Response Spectrophotometer). Piroxicam-free microspheres were treated similarly, and 
the absorbance from their supernatant was subtracted from all measurements.    
 
4.2.5. Microsphere Characterization 
Imaging of microspheres was performed with a LEO-VP1530 field emission 
scanning electron microscope. The mean diameter was quantitatively determined by 
measuring ~1000 microspheres from the SEM micrographs using the Scion Image 
Analysis software. The pixel to distance ratio for each micrograph was entered into the 
software, and the edges of the spheres were specified by hand. The number of 
microspheres (~1000) measured for each population was sufficient to provide an 
accurate mean diameter (Table 4.1).  
 
4.3. Mathematical Model 
The theoretical model developed in Section 3.3 accounts for microsphere size and 
polymer molecular weight, and is used in this Section to predict drug release profiles 
from PLG microspheres having different size distribution and polymer molecular 
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weight. A brief description of the model is included in this Section for completeness; 
however, more details are included in Section 3.3.  
The PLG microspheres were prepared by co-dissolving the polymer and the drug in 
DCM which results in a monolithic solution. Desorption of the drug from monolithic 
systems was first described by Crank in 1956 [84]. Solving the one-dimensional mass 
diffusion equation for a sphere (Equation (3.6)), with the appropriate boundary 
conditions, gives the cumulative release equation for the total amount of diffusing drug 
leaving a sphere (Equation (3.8)) [84].   
The drug diffusion coefficient in the cumulative release equation (D(t)) is time 
dependent due to bulk degradation of the polymer matrix. As the polymer molecular 
weight (Mw) decreases, the drug has more available space to diffuse through the polymer 
chains, and so the diffusion coefficient increases. The dependence of diffusion 
coefficient of piroxicam on PLG molecular weight was investigated by Raman et al. 
[79], and is expressed in Equation (3.9). To account for the initial burst release, an initial 
diffusivity (D0) is used as a fitting parameter. D0 is used until the time dependent 
diffusivity D(Mw) is larger than D0.  
Hydrolysis, which causes bulk degradation of PLG polymer, starts with water 
uptake. The degradation process, which results in a decrease in the polymer molecular 
weight caused by random ester cleavage, is expressed in Equation (3.10) [13]. In this 
Section we investigate drug release from microspheres having different initial polymer 
molecular weights. This is implemented into the mathematical model by changing the 
value of polymer molecular weight at time t = 0 (Mw(0)) in Equation (3.10).  
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The microsphere populations prepared in this work has a non-uniform size 
distribution. In this Section, the size distribution of the microsphere populations is 
represented by the mass/volume moment mean diameter (d43), also known as De 
Brouckere mean diameter, which is the center of gravity of the mass/volume fraction 
size distribution.  
 
4.4. Numerical Optimization Technique  
A numerical optimization technique is developed, based on the least squares method, 
to compute the optimum proportions at which individual microsphere populations can be 
combined to attain desired release kinetics. An optimization problem can be formulated 
mathematically as follows [93-97]: 
 
)(: fEMinimize                                                           (4.1) 
Subject to Sf ∈  
 
where E(f) is the objective function to be minimized, and f is an n x 1 vector of design 
parameters whose values are to be determined. For a solution to be feasible, it must 
belong to the constraint set S, which is a subset of the space n x 1 column vectors R
n.
. 
When S = R
n
, then the problem is an unconstrained optimization. In general, the 
constraint set is a collection of equality and inequality constraints on f.  Few of the 
optimization techniques are available for finding the global minimum of a function. 
Instead, it is typical to search for a local minimum.  
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Here the objective function is the cumulative error between the target release profile 
and a linear combination of the available profiles:  
 
2
1
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iinnii TMfMfMffE                                  (4.2) 
 
where m is the total number of points at which the profiles are evaluated, n is the total 
number of profiles to be combined, M1…Mn are the individual profiles to be combined, 
f1…fn are the mass fractions of the individual populations to be combined, and T is the 
target profile. 
  
4.4.1. Steepest Descent Method  
The steepest descent
 
method [93-95] is used in this work to solve the optimization 
problem. Starting with an initial guess, 0f , we determine a search direction, 0d , and 
perform a line search along that direction. The result of the line search is taken as an 
updated estimate, and the process is repeated. The search direction is determined by 
evaluating the gradient vector of partial derivatives of E with respect to the components 
of f  [93]:     
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where )( fE∇ is the direction of steepest ascent, and )(0 fEd −∇=  is the direction of 
steepest descent. If jα denotes the optimal step length resulting from searching along the 
direction jd , starting from the point jf , then the values of f are updated as follows:  
 
)(
1
fEff
j
k
jj
k
j
k ∇−=
+ α ;     nk ≤≤1                                  (4.4) 
 
where j denotes the iteration number. The iterative process is repeated until the 
components of the direction vector jd  fall below a user-specified error tolerance, ε. 
  
4.5. Results and Discussion 
4.5.1. In Vitro Drug Release Kinetics 
Figure 4.1 shows experimentally measured in vitro release from PLG microspheres 
having different size distribution and polymer molecular weight. The release profiles 
shown in the figure are normalized to the total amount of drug release at the end of the 
study, which was within 10% of the experimental loading shown in Table 4.1. The mean 
diameters (d43) of the microspheres range from 12.8 µm to 83.2 µm, and the Mw ranges 
between 18 kDa and 55 kDa (Table 4.1). Inspection of Figure 4.1 reveals that 
microsphere size is a major determinant of the release profile, and drug initial release 
rate decreased with increase in microsphere size, which confirms the results obtained in 
Section 3.4.2. This is also consistent with Fick’s law of diffusion which attributes this 
decrease in drug release rate to an increase of diffusion pathways (reduced surface area  
  
91 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20 25 30 35 40
Time (days)
C
u
m
u
u
la
ti
v
e
 F
ra
c
ti
o
n
 R
e
le
a
s
e
d
55 kDa - 60-93 µm
55 kDa - 20-40 µm
55 kDa - 0.2-20 µm
18 kDa - 63-90 µm
18 kDa - 20-40 µm
18 kDa - 0.2-20 µm
 
Figure 4.1 Effect of microsphere size and polymer molecular weight on piroxicam release from PLG 
microspheres. 
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to volume ratio for large spheres). In addition, inspection of Figure 4.1 reveals that 
polymer molecular weight is also a major determinant of the release profile, and drug 
initial release rate decreased with increasing polymer molecular weight. As the polymer 
molecular weight is increased, the drug has less available space to diffuse through the 
polymer chains, and the diffusion coefficient decreases, which results in reduced initial 
drug release rates. The combined effect of varying the microsphere size and polymer 
molecular weight resulted in release profiles having different durations (10 to 28 days) 
and shapes (first-order, near zero-order, and sigmoidal). 
 
4.5.2. Model Results 
The Matlab program developed in the previous Section was used to solve the 
cumulative release equation (Equation (3.8)), and predict the release of piroxicam from 
PLG microspheres having different mean diameters and polymer molecular weights. 
Dependence of diffusivity on molecular weight was modeled using Equation (3.9). To 
account for the initial burst release, an initial diffusivity (D0) is used as a fitting 
parameter. D0 is used until the time dependent diffusivity D(Mw) is larger than D0. Since 
the molecular weight of PLG polymer varies with time, it was modeled using Equation 
(3.10). Size distribution of the microspheres was represented in the mathematical model 
by the volume moment mean diameter. As mentioned previously, the volume moment 
mean diameter is the center of gravity of the volume fraction size distribution. It is 
evident from Figure 4.2 that the release profiles generated by the model are in good  
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Figure 4.2 Comparison of model profiles to experimental results of piroxicam loaded PLG 
microspheres: (a) 55 kDa, 63 – 90 µm;  (b) 55 kDa,  20 – 40 µm; (c) 55 kDa, 0.2 – 20 µm; (d) 18 kDa, 
63 – 90 µm; (e) 18 kDa, 20 – 40 µm; and (f) 18 kDa, 0.2-20 µm.  
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Figure 4.2 Continued 
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Figure 4.2 Continued 
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agreement with the experimental drug release data for the different microsphere 
populations. 
 
4.5.3. Release from Mixtures of Individual Microsphere Populations 
Based on the different shapes of the individual release profiles depicted in Figure 
4.1, it might be possible to achieve desired release rates by mixing appropriate 
proportions of two or more individual microsphere populations. To this end, a numerical 
optimization technique was developed, based on the least squares method, that computes 
the optimum proportions at which individual microsphere populations can be combined 
to attain desired release kinetics.   
To test this hypothesis, we constructed several desired release profiles (Figure 4.3), 
in particular, pulsatile, zero-order, and near zero-order release profiles. The ideal desired 
drug release profile is one that initiates the optimum response in a patient. Pulsatile 
release [5,52-54] is attractive for vaccine delivery, as the drug release formulation can be 
designed to deliver distinct pulses which solves the need for booster shots. Zero-order 
release [49-51] is desired for a wide range of drugs because it maintains a constant level 
of drug concentration well within the therapeutic window for extended time periods. In 
addition, it is sometimes desirable to have a near-zero order release profile where a small 
amount of drug is released in a burst, followed by constant release over extended period. 
After the desired release profiles were constructed, the numerical optimization technique 
was utilized to identify the best candidates to be combined and their optimum 
proportions. The initial goal was to achieve the desired profiles by combining two 
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individual populations. In Figure 4.3, the dashed line is the target profile, while the solid 
line is the predicted optimum release. To validate the predicted release, in vitro release 
experiments of a mixture of the individual populations at the determined proportions 
were performed. 
In Figure 4.3 (a) the desired release has a pulsatile profile that delivers its first pulse 
(~ 45% of the total drug load) in the first 3 days, and then delivers its second pulse (~ 
40% of the total drug load) from day 22 to day 28. Using the numerical optimization 
technique, it was determined that the optimum release can be achieved by mixing the 63-
90 µm / 55 kDa microsphere population and the 0.2-20 µm / 18 kDa microsphere 
population at mass fractions of 0.47 and 0.53 respectively. From inspection of Figure 4.3 
(a), it is evident that the predicted optimum release profile is in good agreement with the 
desired release (R
2
 = 0.988), and that the pulsatile release was successfully achieved by 
combining microsphere populations.  
The desired release in Figure 4.3 (b) has a zero-order profile that delivers its drug 
load at constant rate for 28 days (3.57% of total drug load delivered per day). Using the 
numerical optimization technique, it was determined that the optimum release can be 
achieved by mixing the 63-90 µm / 55 kDa microsphere population and the 20-40 µm / 
18 kDa microsphere population at mass fractions of 0.43 and 0.57 respectively. 
Inspection of Figure 4.3 (b) shows that designing a truly zero-order release by mixing 
two individual populations had a limited success (R
2
 = 0.965). 
The desired release in both Figure 4.3 (c) and Figure 4.3 (d) has a near zero-order 
profile that starts with a high initial drug release rate for two (2) days and then shifts to a 
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(a) 
 
Figure 4.3 Combining appropriate proportions of two individual PLG microsphere populations to 
achieve desired drug release profiles: a) pulasatile, b) zero-order, c) near zero-order, and d) near 
zero-order. 
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(b) 
 
Figure 4.3 Continued 
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(c) 
 
Figure 4.3 Continued 
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(d) 
 
Figure 4.3 Continued 
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lower release rate for the additional 23 days. In Figure 4.3 (c) the desired release delivers 
20% of the total drug load in the first two (2) days, while the desired release in Figure 
4.3 (d) delivers 30% of the total drug load in that same time period.  The optimum 
release in Figure 4.3 (c) was achieved by mixing the 20-40 µm / 55 kDa microsphere 
population and the 20-40 µm / 18 kDa microsphere population at mass fractions of 0.53 
and 0.47 respectively. It is evident from Figure 4.3 (c) that the predicted optimum 
release profile is in good agreement with the desired release (R
2
 = 0.994). Alternatively, 
the optimum release in Figure 4.3 (d) was achieved by mixing the 20-40 µm / 55kDa 
microsphere population and the 0.2-20 µm / 18 kDa microsphere population at mass 
fractions of 0.63 and 0.37 respectively. From inspection of Figure 4.3 (d), it is evident 
that the predicted optimum release profile is in fair agreement with the desired release 
(R
2
 = 0.981). 
In addition, Figure 4.3 (a-d) shows that the experimental optimum release profiles 
are all in good agreement with the predicted optimum release profiles. This validates the 
predicted release profiles, and shows that the measured release from a combination of 
microsphere populations corresponds to a mass-weighted linear combination of the 
individual profiles. 
Given the agreement between the predicted release profiles and the experimental 
data, the optimization technique was then utilized to achieve the desired release kinetics 
by combining multiple release profiles. The numerical algorithm was developed to 
automatically consider the different combinations of microsphere populations and report 
the optimum proportions and the cumulative error associated with each combination. 
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The number of combinations (N) for selecting q profiles from a total of p available 
profiles (p is equal to six in this work) can be expressed as follows [98]: 
 
)!(!
!
qpq
p
N
−
=                                                               (4.5) 
 
For example, to achieve a desired release, there are 15 different combinations for 
selecting two profiles out of a total of six profiles, and 20 different combinations for 
selecting three profiles, and so forth. The total number of combinations (Ntot) is equal to 
57 and can be expressed as follows: 
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In Figure 4.4 the desired release profiles, previously described in Figure 4.3, are 
achieved by combining three individual populations. Combining more than three profiles 
to achieve the desired release kinetics did not provide any improvement in the optimum 
release. Comparison of Figure 4.4 (a) with Figure 4.3 (a) reveals that combining three 
individual profiles provides a marginally improved fit (R
2 
= 0.992) to the desired release 
profile than combining two profiles (R
2
 = 0.988). The same conclusion can be made by 
comparing Figure 4.4 (c) (R
2
 = 0.998) with Figure 4.3 (c) (R
2
 = 0.994). This slight 
improvement in the optimum release should be weighed against the additional effort  
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(a) 
 
Figure 4.4 Combining appropriate proportions of multiple individual PLG microsphere populations 
to achieve desired drug release profiles: a) pulasatile, b) zero-order, c) near zero-order, and d) near 
zero-order. 
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(b) 
 
 
Figure 4.4 Continued 
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(c) 
 
 
 
Figure 4.4 Continued 
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(d) 
 
 
Figure 4.4 Continued 
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required to prepare and combine three microsphere populations versus two microsphere 
populations.  
Alternatively, inspection of Figure 4.4 (b) shows that the optimum release obtained 
by combining three individual profiles provides a considerably better fit (R
2 
= 0.993) to 
the desired release, than was achieved by combining two profiles (R
2 
= 0.965; Figure 4.3 
(b)).  The same conclusion can be made by comparing the optimum release in Figure 4.4 
(d) (R
2 
= 0.998) with the optimum release in Figure 4.3 (d) (R
2 
= 0.98). 
 More complex drug release profiles can be achieved by mixing individual PLG 
microsphere populations having a wider range of sizes and polymer molecular weights. 
In addition, other key parameters such as polymer composition in general and 
lactide/glycolide ratio in particular, can be utilized to prepare PLG microspheres having   
a wide variation of drug release profiles. In Appendix A, a drug release profile having 
three distinct pulses is achieved by combining the predicted release from a PLG 
microsphere population having a mean diameter of 160 µm, and a polymer molecular 
weight of 220 kDa, with the 63-90 µm / 55 kDa and the 0.2-20 µm / 18 kDa microsphere 
populations. The numerical optimization technique was used to determine the optimum 
proportions at which the individual microsphere populations need to be combined.    
     
4.6. Conclusions 
Piroxicam loaded PLG microspheres have been prepared using the oil-in-water (o-w) 
emulsion technique. The effect of microsphere mean diameter, and polymer molecular 
weight on drug release rate from the microspheres was investigated. The mathematical 
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model developed in the previous Section was used to predict drug release from PLG 
microspheres having different size and polymer molecular weight. A numerical 
optimization technique was developed to tailor desired drug release profiles by 
combining individual microsphere populations at appropriate proportions. It was shown 
that the initial drug release rate decreased with an increase in polymer molecular weight. 
The combined effect of varying the microsphere size and polymer molecular weight 
resulted in release profiles having different durations (10 to 28 days) and shapes (first-
order, zero-order, sigmoidal). The model results were in good agreement with the 
experimental results. It was also shown that the mixture release profiles corresponded to 
a mass weighted linear combination of the individual profiles. Using the numerical 
optimization technique, it was possible to determine the appropriate proportions of 
individual microspheres that generate the desired release profiles, in particular, zero-
order, and pulsatile.     
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5. CONCLUSIONS AND RECOMMENDATIONS 
This work has investigated the effect of various parameters on small molecule 
release from PLG microspheres prepared using an emulsion technique. Due to the 
importance of microsphere size on release kinetics, a quantitative study has been 
performed on the microsphere size distributions and a fluid mechanics based 
mathematical correlation was developed to predict the mean diameter of the 
microspheres prepared. The correlation was validated by comparison with experimental 
results for a wide range of Wem. This correlation is valid for non-coalescing dispersions, 
with the dispersed phase having low viscosity, and volume fraction. The size distribution 
of PLG microspheres prepared using the emulsion technique was described by the 
Rosin-Rammler distribution function. The effect of microsphere mean diameter, 
polydispersity, polymer initial molecular weight, and polymer degradation on therapeutic 
drug release rate from the microspheres was investigated experimentally. Based on the 
experimental results, a mathematical model that predicts drug release from polydisperse 
PLG microspheres was developed. The model accounts for the effects of diffusion, 
polymer initial molecular weight, polymer degradation, and microsphere size 
distribution. Finally, a numerical optimization technique was developed to tailor desired 
therapeutic drug release profiles by combining individual microsphere populations at 
appropriate proportions. The significant conclusions of this work are summarized below. 
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• The derived fluid mechanics based mathematical correlation provided a good 
estimate to the microsphere populations mean diameter over a wide range of Wem 
• The Rosin-Rammler distribution function provided a good description of the size 
distribution of the PLG microspheres prepared using the solvent extraction 
technique. 
• Microsphere size had a significant effect on the drug release kinetics, and the 
initial drug release rate decreased with increase in microsphere size. Also, the 
release profile changed from first order to concave upward as microsphere size 
was increased. 
• Polymer initial molecular weight had a significant effect on release kinetics, and 
it was shown that the initial drug release rate decreased with an increase in 
polymer molecular weight. 
• Polydispersity did not have a significant effect on drug release rate for 
populations having a polydispersity parameter (b) larger than 3. Alternatively, for 
distributions having a value of b close to or below 3, incorporating the size 
distribution of the population into the model provided a better fit to the 
experimental results. Also polydispersity was not believed to be the main cause 
for the initial “burst” release 
• The model results were in good agreement with experimental results, and thus 
can be used to predict therapeutic drug release from polydisperse populations of 
microspheres. 
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• The combined effect of varying the microsphere size and polymer molecular 
weight resulted in release profiles having different durations (10 to 28 days) and 
shapes (first-order, zero-order, and sigmoidal). 
• It was shown that the mixture release profiles corresponded to a mass weighted 
linear combination of the individual profiles. 
• Using the numerical optimization technique, it was possible to determine the 
appropriate proportions of individual microspheres that generate the desired 
release profiles, in particular, zero-order, and pulsatile. 
 
The following recommendations are proposed for future work: 
• Expand the current study to investigate additional key parameters that can be 
utilized to control the release rate of pharmaceuticals from microspheres, in 
particular polymer composition (polymer chemistry and copolymer ratio).  
• Rapid developments in the field of molecular biology and biotechnology resulted 
in generation of many macromolecular therapeutic drugs including peptides, 
proteins, polysaccharides and nucleic acids. The methodology developed in this 
work for small molecule release can be applied to tailor drug release kinetics of 
macromolecules from polymeric microspheres. 
• Determining the mean diameter of the microsphere populations by measuring 
microspheres from SEM micrographs using the Scion Image Analysis software 
was time consuming. Laser diffraction and electrozone sensing techniques can be 
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used instead to provide faster and more accurate measurements for the mean 
diameter. 
• The conventional microsphere preparation impeller set-up used in this work 
produces microsphere populations of non-uniform size distribution. New 
manufacturing techniques are being developed to produce monodisperse 
microsphere populations, which eliminates the need for sieving. 
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APPENDIX A 
DRUG RELEASE PROFILE HAVING THREE DISTINCT PULSES  
Here we design a three pulse drug release profile using the mathematical model 
developed in Section 3, and the numerical optimization technique developed in Section 
4. In Figure A.1, the dashed line is the target profile, while the solid line is the predicted 
optimum release. The target release has a pulsatile profile that delivers its first pulse (~ 
25% of the total drug load) in the first 3 days, and then delivers its second pulse (~ 29% 
of total drug load) from day 22 to day 28, and finally delivers its third pulse (~ 28 % of 
total drug load) from day 38 to day 44. The mathematical model developed in Section 3, 
was used to predict drug release from PLG microspheres having a mean diameter of 160 
µm and a molecular weight of 220 kDa (population A in figure A.1). Then using the 
numerical optimization technique, it was determined that the optimum release can be 
achieved by mixing the 160 µm / 220 kDa microsphere population, the 63-90 µm / 55 
kDa micosphere population, and the 0.2-20 µm /18 kDa microsphere population at mass 
fractions of 0.38, 0.35, and 0.27 respectively. From inspection of Figure A.1, it is evident 
that the predicted optimum release is in good agreement with the desired release (R
2 
= 
0.998), which shows that drug release having three distinct pulses can be achieved by 
combining individual microsphere populations.     
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Figure A.1 Designing a drug release profile having three distinct pulses. 
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